Glycine Treatment of Prodromal Symptoms

This study has been completed.

First Received: December 20, 2005 Last Updated: March 25, 2008 History of Changes

Sponsors and Collaborators:	Yale University Stanley Medical Research Institute
Information provided by:	Yale University
ClinicalTrials.gov Identifier:	NCT00268749

Purpose

This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.

Condition	Intervention	Phase
Schizophrenia	Drug: glycine Drug: placebo	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study
Official Title:	Glycine Treatment of Prodromal Symptoms

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia

Drug Information available for: Glycine

U.S. FDA Resources

Further study details as provided by Yale University:

Enrollment:	6
Study Start Date:	July 2002

Arms	Assigned Interventions
1: Experimental	Drug: glycine 0.8 g/kg/day
2: Placebo Comparator	Drug: placebo placebo

Eligibility

Ages Eligible for Study:	14 Years to 35 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

age 14-35
meets SIPS criteria for psychosis prodrome

Exclusion Criteria:

current antipsychotic medication
more than 4 weeks of antipsychotic medication lifetime

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00268749

Sponsors and Collaborators

Yale University

Stanley Medical Research Institute

Investigators

Principal Investigator:

Scott W Woods, MD

Yale University

More Information

No publications provided

Study ID Numbers:	02T-175
Study First Received:	December 20, 2005
Last Updated:	March 25, 2008
ClinicalTrials.gov Identifier:	NCT00268749 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Schizophrenia
Neurotransmitter Agents
Glycine

Mental Disorders
Psychotic Disorders
Schizophrenia and Disorders with Psychotic Features

Additional relevant MeSH terms:

Schizophrenia
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Glycine
Mental Disorders

Physiological Effects of Drugs
Glycine Agents
Pharmacologic Actions
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on September 10, 2009